Why Amarin Is Tanking After Hours

Before you go, we thought you'd like these...
Before you go close icon

Amarin is plunging more than 20% in after-hours trading, after disclosing that it will be hiring a sales force for its flagship drug Vascepa. Investors were hoping for a swift buyout, and tonight's late-breaking announcement may be a blow to that happening. Management insisted that all options are still on the table ahead of a potential NCE status update next week, but this is still widely seen as a blow to a buyout or partnership. Watch health-care analysts David Williamson and Max Macaluso discuss where this leaves Amarin investors in the following video.

Today's events are an easy reminder that the biotech space can make or break investors overnight, and while Amarin might not disappear into thin air, the success of its new triglyceride-lowering drug is key to the company's future success or failure. The company has huge potential, but don't invest a dollar before reading everything you need to know about Amarin. You can start now with top Fool.com analyst Max Macaluso's premium research report. Click here now to keep reading.

 

The article Why Amarin Is Tanking After Hours originally appeared on Fool.com.

David Williamson owns shares of Amarin plc (ADR). Follow him on Twitter @MotleyDavidThe Motley Fool has no positions in the stocks mentioned above. Motley Fool newsletter services recommend GlaxoSmithKline. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.

Read Full Story

Want more news like this?

Sign up for Finance Report by AOL and get everything from business news to personal finance tips delivered directly to your inbox daily!

Subscribe to our other newsletters

Emails may offer personalized content or ads. Learn more. You may unsubscribe any time.

From Our Partners